Ind-Swift Laboratories Inkomsten in het verleden

Verleden criteriumcontroles 5/6

Ind-Swift Laboratories is de winst gegroeid met een gemiddeld jaarlijks percentage van 84.4%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 13.4%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 7.4% per jaar. Het rendement op eigen vermogen van Ind-Swift Laboratories is 36.9%, en het heeft een nettomarge van 50.3%.

Belangrijke informatie

84.4%

Groei van de winst

84.6%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	17.5%
Inkomstengroei	7.4%
Rendement op eigen vermogen	36.9%
Nettomarge	50.3%
Volgende winstupdate	14 Feb 2025

Recente prestatie-updates uit het verleden

There Are Some Reasons To Suggest That Ind-Swift Laboratories' (NSE:INDSWFTLAB) Earnings Are A Poor Reflection Of Profitability

Nov 20

Shareholders In Ind-Swift Laboratories (NSE:INDSWFTLAB) Should Look Beyond Earnings For The Full Story

May 21

Recent updates

There Are Some Reasons To Suggest That Ind-Swift Laboratories' (NSE:INDSWFTLAB) Earnings Are A Poor Reflection Of Profitability

Nov 20

Ind-Swift Laboratories Limited's (NSE:INDSWFTLAB) Revenues Are Not Doing Enough For Some Investors

Oct 20

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Stock Rockets 29% But Many Are Still Ignoring The Company

Jul 02

Shareholders In Ind-Swift Laboratories (NSE:INDSWFTLAB) Should Look Beyond Earnings For The Full Story

May 21

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Surges 26% Yet Its Low P/E Is No Reason For Excitement

Apr 13

Here's Why Ind-Swift Laboratories (NSE:INDSWFTLAB) Can Manage Its Debt Responsibly

Dec 28

These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Reasonably Well

Jul 22

Ind-Swift Laboratories (NSE:INDSWFTLAB) Has A Somewhat Strained Balance Sheet

Jul 12

Did Business Growth Power Ind-Swift Laboratories' (NSE:INDSWFTLAB) Share Price Gain of 231%?

Feb 17

We're Not So Sure You Should Rely on Ind-Swift Laboratories's (NSE:INDSWFTLAB) Statutory Earnings

Dec 30

These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Extensively

Nov 11

Is Ind-Swift Laboratories (NSE:INDSWFTLAB) A Risky Investment?

Jun 27

Opbrengsten en kosten

Hoe Ind-Swift Laboratories geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NSEI:INDSWFTLAB Opbrengsten, kosten en inkomsten (INR Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	7,423	3,734	936	0
30 Jun 24	10,037	4,047	1,199	0
31 Mar 24	12,973	4,210	1,582	0
31 Dec 23	12,004	432	1,534	0
30 Sep 23	12,256	513	1,495	0
30 Jun 23	12,375	450	1,410	0
31 Mar 23	12,159	476	1,401	0
31 Dec 22	12,231	113	1,279	0
30 Sep 22	11,571	-2	1,234	0
30 Jun 22	10,691	-11	1,164	0
31 Mar 22	10,529	-21	1,278	0
31 Dec 21	9,754	301	1,163	0
30 Sep 21	9,555	256	1,144	0
30 Jun 21	9,536	111	1,130	0
31 Mar 21	9,068	-31	1,079	0
31 Dec 20	8,776	277	1,097	0
30 Sep 20	8,536	77	1,082	0
30 Jun 20	8,360	-111	1,022	0
31 Mar 20	7,993	-212	1,058	0
31 Dec 19	7,977	-734	1,021	0
30 Sep 19	7,992	-211	1,012	0
30 Jun 19	7,872	-35	929	0
31 Mar 19	7,790	289	1,018	0
31 Mar 18	7,769	220	963	0
31 Mar 17	7,142	-391	765	0
31 Mar 16	6,641	-587	694	0
31 Mar 15	6,778	-1,194	571	0
31 Mar 14	9,738	-1,220	867	78

Kwaliteitswinsten: INDSWFTLAB heeft een hoog niveau van non-cash earnings.

Groeiende winstmarge: De huidige netto winstmarges (50.3%) INDSWFTLAB } zijn hoger dan vorig jaar (4.2%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: INDSWFTLAB is de afgelopen 5 jaar winstgevend geworden en heeft de winst met 84.4% per jaar laten groeien.

Versnelling van de groei: De winstgroei van INDSWFTLAB over het afgelopen jaar ( 628.3% ) overtreft het 5-jarig gemiddelde ( 84.4% per jaar).

Winst versus industrie: De winstgroei INDSWFTLAB over het afgelopen jaar ( 628.3% ) overtrof de Pharmaceuticals -sector 20.5%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 36.9% ) van INDSWFTLAB wordt als hoog beschouwd.

Ind-Swift Laboratories Inkomsten in het verleden

Verleden criteriumcontroles 5/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

There Are Some Reasons To Suggest That Ind-Swift Laboratories' (NSE:INDSWFTLAB) Earnings Are A Poor Reflection Of Profitability

Second quarter 2025 earnings released: EPS: ₹0.07 (vs ₹5.36 in 2Q 2024)

Ind-Swift Laboratories Limited to Report Q3, 2025 Results on Feb 14, 2025

First quarter 2025 earnings released: EPS: ₹0.16 (vs ₹2.92 in 1Q 2024)

Ind-Swift Laboratories Limited to Report Q1, 2025 Results on Aug 12, 2024

Shareholders In Ind-Swift Laboratories (NSE:INDSWFTLAB) Should Look Beyond Earnings For The Full Story

Recent updates

There Are Some Reasons To Suggest That Ind-Swift Laboratories' (NSE:INDSWFTLAB) Earnings Are A Poor Reflection Of Profitability

Second quarter 2025 earnings released: EPS: ₹0.07 (vs ₹5.36 in 2Q 2024)

Ind-Swift Laboratories Limited's (NSE:INDSWFTLAB) Revenues Are Not Doing Enough For Some Investors

Chief Financial Officer recently sold ₹4.2m worth of stock

Ind-Swift Laboratories Limited to Report Q3, 2025 Results on Feb 14, 2025

Investor sentiment deteriorates as stock falls 21%

Ind-Swift Laboratories Limited, Annual General Meeting, Sep 30, 2024

First quarter 2025 earnings released: EPS: ₹0.16 (vs ₹2.92 in 1Q 2024)

Ind-Swift Laboratories Limited to Report Q1, 2025 Results on Aug 12, 2024

Investor sentiment improves as stock rises 24%

Ind-Swift Laboratories Limited Appoints Mr. Param Bir Singh as an Independent Director

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Stock Rockets 29% But Many Are Still Ignoring The Company

New minor risk - Share price stability

Shareholders In Ind-Swift Laboratories (NSE:INDSWFTLAB) Should Look Beyond Earnings For The Full Story

Full year 2024 earnings released: EPS: ₹71.24 (vs ₹8.06 in FY 2023)

New minor risk - Share price stability

Ind-Swift Laboratories Limited to Report Q4, 2024 Results on May 13, 2024

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Surges 26% Yet Its Low P/E Is No Reason For Excitement

Investor sentiment improves as stock rises 15%

Synthimed Labs Private Limited agreed to acquire API and CRAMS business of Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) and Essix Biosciences Limited.

Third quarter 2024 earnings released: EPS: ₹3.29 (vs ₹4.65 in 3Q 2023)

Ind-Swift Laboratories Limited to Report Q3, 2024 Results on Feb 12, 2024

Here's Why Ind-Swift Laboratories (NSE:INDSWFTLAB) Can Manage Its Debt Responsibly

Second quarter 2024 earnings released: EPS: ₹5.36 (vs ₹4.29 in 2Q 2023)

Ind-Swift Laboratories Limited to Report Q2, 2024 Results on Nov 07, 2023

Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) agreed to acquire Ind-Swift Limited (BSE:524652).

Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) agreed to acquire Ind-Swift Limited (BSE:524652).

Synthimed Labs Private Limited agreed to acquire API and CRAMS business of Ind-Swift Laboratories Limited for INR 16.5 billion.

Ind-Swift Laboratories Limited, Annual General Meeting, Sep 30, 2023

Investor sentiment improves as stock rises 19%

First quarter 2024 earnings released: EPS: ₹2.92 (vs ₹3.36 in 1Q 2023)

Ind-Swift Laboratories Limited to Report Q1, 2024 Results on Aug 09, 2023

These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Reasonably Well

Group Head of Human Resources recently sold ₹3.3m worth of stock

Investor sentiment improves as stock rises 16%

Chief Accounts Officer recently sold ₹1.6m worth of stock

Full year 2023 earnings released: EPS: ₹8.06 (vs ₹0.36 loss in FY 2022)

Insufficient new directors

Third quarter 2023 earnings released: EPS: ₹4.65 (vs ₹2.71 in 3Q 2022)

Insider recently sold ₹1.2m worth of stock

Second quarter 2023 earnings released: EPS: ₹4.29 (vs ₹4.14 in 2Q 2022)

Insider recently sold ₹1.6m worth of stock

Ind-Swift Laboratories Limited to Report Fiscal Year 2023 Results on May 30, 2023

First quarter 2023 earnings released: EPS: ₹3.36 (vs ₹3.18 in 1Q 2022)

Ind-Swift Laboratories Limited, Annual General Meeting, Sep 30, 2022

Ind-Swift Laboratories Limited to Report Q1, 2023 Results on Aug 10, 2022

Full year 2022 earnings released: ₹0.36 loss per share (vs ₹0.53 loss in FY 2021)

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹4.14 (vs ₹1.68 in 2Q 2021)

Investor sentiment deteriorated over the past week

Soft Air General Trading LLC agreed to acquire Ind-Swift Middle East FZ-LLC from Ind-Swift Laboratories Limited (BSE:532305) for approximately $2 million.

First quarter 2022 earnings released: EPS ₹3.18 (vs ₹0.77 in 1Q 2021)

High number of new directors

Ind-Swift Laboratories (NSE:INDSWFTLAB) Has A Somewhat Strained Balance Sheet

Full year 2021 earnings released: ₹0.53 loss per share (vs ₹4.28 loss in FY 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Insider recently sold ₹1.0m worth of stock

Independent Director has left the company

Insider recently sold ₹1.4m worth of stock

Investor sentiment improved over the past week

Insider recently sold ₹2.1m worth of stock

Did Business Growth Power Ind-Swift Laboratories' (NSE:INDSWFTLAB) Share Price Gain of 231%?

Third quarter 2021 earnings released: EPS ₹1.95 (vs ₹1.90 loss in 3Q 2020)

Ind-Swift Laboratories Limited to Report Q3, 2021 Results on Feb 12, 2021